Telmisartan ameliorates insulin sensitivity by activating the AMPK/SIRT1 pathway in skeletal muscle of obese db/db mice

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Shiota, Asuka ^a   Shimabukuro, Michio ^a   Fukuda, Daiju ^a   Soeki, Takeshi ^a   Sato, Hiromi ^a   Uematsu, Etsuko ^a   Hirata, Yoichiro ^a   Kurobe, Hirotsugu ^a   Maeda, Norikazu ^b   Sakaue, Hiroshi ^a   Masuzaki, Hiroaki ^c   Shimomura, Iichiro ^b   Sata, Masataka ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Adiponectin; AMP activated protein kinase; Obesity; Peroxisome proliferator activated receptor ; SIRT1

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; SIRTUIN 1; TELMISARTAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; HEART MUSCLE CELL; IN VITRO STUDY; IN VIVO STUDY; INSULIN SENSITIVITY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ADIPOCYTES; ADMINISTRATION, ORAL; AMP-ACTIVATED PROTEIN KINASES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANILIDES; ANIMALS; BENZIMIDAZOLES; BENZOATES; CELL LINE; DIABETES MELLITUS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FATTY ACID TRANSPORT PROTEINS; GLUCOSE TRANSPORTER TYPE 4; HYPERTROPHY; INSULIN; ISLETS OF LANGERHANS; MALE; MICE; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; NAD; OBESITY; PHOSPHORYLATION; PPAR GAMMA; RNA, MESSENGER; SIGNAL TRANSDUCTION; SIRTUIN 1; TIME FACTORS; TRANS-ACTIVATORS;

EID: 84868457722     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-139     Document Type: Article

References (41)

1. Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 2012, 13:225-238.
2. Fulco M, Schiltz RL, Iezzi S, et al. Sir2 regulates skeletal muscle differentiation as a potential sensor of the redox state. Mol Cell 2003, 12:51-62. 10.1016/S1097-2765(03)00226-0, 12887892.
3. Vinciguerra M, Fulco M, Ladurner A, Sartorelli V, Rosenthal N. SirT1 in muscle physiology and disease: lessons from mouse models. Dis Model Mech 2010, 3:298-303. 10.1242/dmm.004655, 2860850, 20354108.
4. Tonkin J, Villarroya F, Puri PL, Vinciguerra M. SIRT1 signaling as potential modulator of skeletal muscle diseases. Curr Opin Pharmacol 2012, Epub ahead of print.
5. Zhang BB, Zhou G, Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 2009, 9:407-416. 10.1016/j.cmet.2009.03.012, 19416711.
6. Ouyang J, Parakhia RA, Ochs RS. Metformin activates AMP kinase through inhibition of AMP deaminase. J Biol Chem 2011, 286:1-11. 10.1074/jbc.M110.121806, 3012963, 21059655.
7. Cool B, Zinker B, Chiou W, et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 2006, 3:403-416. 10.1016/j.cmet.2006.05.005, 16753576.
8. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122. 10.1016/j.cell.2006.11.013, 17112576.
9. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004, 43:993-1002. 10.1161/01.HYP.0000123072.34629.57, 15007034.
10. Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension 2006, 48:51-57. 10.1161/01.HYP.0000225402.69580.1d, 16717145.
11. Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006, 47:1003-1009. 10.1161/01.HYP.0000215181.60228.f7, 16567593.
12. Pershadsingh HA, Kurtz TW. Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. Diabetes Care 2004, 27:1015.
13. Shimabukuro M, Tanaka H, Shimabukuro T. Effects of telmisartan on fat distribution in subjects with the metabolic syndrome. J Hypertens 2007, 25:841-848. 10.1097/HJH.0b013e3280287a83, 17351377.
14. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004, 10:355-361. 10.1038/nm1025, 15057233.
15. Kurtz TW. Beyond the classic angiotensin-receptor-blocker profile. Nat Clin Pract Cardiovasc Med 2008, 5:S19-26.
16. Chaudhary N, Pfluger PT. Metabolic benefits from Sirt1 and Sirt1 activators. Curr Opin Clin Nutr Metab Care 2009, 12:431-437. 10.1097/MCO.0b013e32832cdaae, 19474719.
17. Sugden MC, Caton PW, Holness MJ. PPAR control: it's SIRTainly as easy as PGC. J Endocrinol 2010, 204:93-104. 10.1677/JOE-09-0359, 19770177.
18. Reeves PG, Nielsen FH, Fahey GC. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993, 123:1939-1951.
19. Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000, 28:149-67.
20. Goyal S, Arora S, Bhatt TK, Das P, Sharma A, Kumari S, Arya DS. Modulation of PPAR-gamma by telmisartan protects the heart against myocardial infarction in experimental diabetes. Chem Biol Interact 2010, 185:271-80. 10.1016/j.cbi.2010.03.030, 20307515.
21. Sakai T, Sakaue H, Nakamura T, Okada M, Matsuki Y, Watanabe E, Hiramatsu R, Nakayama K, Nakayama KI, Kasuga M. Skp2 controls adipocyte proliferation during the development of obesity. J Biol Chem 2007, 282:2038-2046.
22. Shimabukuro M, Ohneda M, Lee Y, Unger RH. Role of nitric oxide in obesity-induced beta cell disease. J Clin Invest 1997, 100:290-5. 10.1172/JCI119534, 508191, 9218505.
23. Yaffe D, Saxel O. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature 1977, 270:725-727. 10.1038/270725a0, 563524.
24. Iwabu M, Yamauchi T, Okada-Iwabu M, et al. Adiponectin and AdipoR1 regulate PGC-1α and mitochondria by Ca2+ and AMPK/SIRT1. Nature 2010, 464:1313-1319. 10.1038/nature08991, 20357764.
25. Qiao L, Lee B, Kinney B, Yoo HS, Shao J. Energy intake and adiponectin gene expression. Am J Physiol Endocrinol Metab 2011, 300:E809-816. 10.1152/ajpendo.00004.2011, 3093972, 21325106.
26. Caton PW, Kieswich J, Yaqoob MM, Holness MJ, Sugden MC. Metformin opposes impaired AMPK and SIRT1 function and deleterious changes in core clock protein expression in white adipose tissue of genetically-obese db/db mice. Diabetes Obes Metab 2011, 13:1097-1104. 10.1111/j.1463-1326.2011.01466.x, 21733059.
27. Clark SJ, Falchi M, Olsson B, et al. Association of sirtuin 1 (SIRT1) gene SNPs and transcript expression levels with severe obesity. Obesity 2012, 20:178-185. 10.1038/oby.2011.200, 21760635.
28. Lee GH, Proenca R, Montez JM, et al. Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996, 379:632-635. 10.1038/379632a0, 8628397.
29. Rong JX, Qiu Y, Hansen MK, et al. Adipose mitochondrial biogenesis is suppressed in db/db and high-fat diet-fed mice and improved by rosiglitazone. Diabetes 2007, 56:1751-1760. 10.2337/db06-1135, 17456854.
30. Nishida Y, Takahashi Y, Nakayama T, Soma M, Asai S. Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study. Cardiovasc Diabetol 2011, 10:74. 10.1186/1475-2840-10-74, 3163179, 21827713.
31. Liang F, Kume S, Koya D. SIRT1 and insulin resistance. Nature Rev Endocrinol 2009, 5:367-373.
32. Cantó C, Auwerx J. PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 2009, 20:98-105. 10.1097/MOL.0b013e328328d0a4, 19276888.
33. Banks AS, Kon N, Knight C, et al. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab 2008, 8:333-341. 10.1016/j.cmet.2008.08.014, 3222897, 18840364.
34. Bordone L, Cohen D, Robinson A, et al. SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell 2007, 6:759-767. 10.1111/j.1474-9726.2007.00335.x, 17877786.
35. Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450:712-716. 10.1038/nature06261, 2753457, 18046409.
36. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157. 10.1053/j.gastro.2007.03.054, 17498508.
37. Westerink J, Visseren FLJ. Pharmacological and non-pharmacological interventions to influence adipose tissue function. Cardiovasc Diabetol 2011, 10:13. 10.1186/1475-2840-10-13, 3039566, 21276223.
38. Bourron O, Daval M, Hainault I, Hajduch E, Servant JM, Gautier JF, et al. Biguanides and thiazolidinediones inhibit stimulated lipolysis in human adipocytes through activation of AMP-activated protein kinase. Diabetologia 2010, 53:768-778. 10.1007/s00125-009-1639-6, 20043143.
39. Saitoh Y, Hongwei W, Ueno H, Mizuta M, Nakazato M. Telmisartan attenuates fatty-acid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta-cells. Diabetes Metab 2009, 35:392-397. 10.1016/j.diabet.2009.04.005, 19713141.
40. Yuan L, Li X, Li J, Li HL, Cheng SS. Effects of renin-angiotensin system blockade on the islet morphology and function in rats with long-term high-fat diet. Acta Diabetol 2010,
41. Chen D, Bruno J, Easlon E, et al. Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev 2008, 22:1753-1757. 10.1101/gad.1650608, 2492662, 18550784.